Overview

Phase III Study on HMPL-523 for Treatment of ITP

Status:
Not yet recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
This is a randomized, double blinded, placebo-controlled phase III clinical trial in adult patients with immune thrombocytopenia.
Phase:
Phase 3
Details
Lead Sponsor:
Hutchison Medipharma Limited